Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study

BACKGROUND: There is limited experience regarding the safety and efficacy of checkpoint inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological cancers as they are generally excluded from clinical trials due to risk of exacerbations. METHODS: This multicenter retrospectiv...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Martinez Chanza, Nieves, Xie, Wanling, Issa, Majd, Dzimitrowicz, Hannah, Tripathi, Abhishek, Beuselinck, Benoit, Lam, Elaine, Zakharia, Yousef, Mckay, Rana, Shah, Sumit, Mortazavi, Amir, R. Harrison, Michael, Sideris, Spyridon, Kaymakcalan, Marina D, Abou Alaiwi, Sarah, Nassar, Amin H, Nuzzo, Pier Vitale, Hamid, Anis, K Choueiri, Toni, C Harshman, Lauren
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2020
Aiheet:
Clinical/Translational Cancer Immunotherapy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7174076/
https://ncbi.nlm.nih.gov/pubmed/32217762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000538
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia